Dr Anna Sureda, President of the European Society for Blood and Marrow Transplantation (EBMT), shares her highlights from the 49th Annual Meeting held in Paris, the first in-person event in three years. These include advances in treating major complications of transplantation in both adults and paediatric patients and further knowledge in managing new cellular therapies such as CAR-T.
Disclosures: Anna Sureda has received honoraria from Alexion, Amgen, BMS/Celgene, Gilead Kite, Janssen, MSD, Novartis, Roche, Sanofi and Takeda, and consultancy fees from BMS/Celgene, Gilead, Janssen, Novartis, Sanofi and Takeda. She is on the speaker’s bureau for and has received research support from Takeda. Non-profit organizations roles include Presidency of the EBMT and presidency of the GETH-TC.
Support: Interview and filming supported by Touch Medical Media Ltd. Interview conducted by Sophie Nickelson.
